



LETTERS TO THE EDITOR

## ***nm23H1* expression and its role in the evolution of non-gastrointestinal malignancies**

Shailendra Kapoor

Shailendra Kapoor, 26-Hoffman Estates, Schaumburg, IL 60197, United States

Author contributions: Kapoor S wrote the draft of the letter.

Correspondence to: Shailendra Kapoor, MD, Physician, 26-Hoffman Estates, Schaumburg, IL 60197,

United States. [shailendrakapoor@yahoo.com](mailto:shailendrakapoor@yahoo.com)

Telephone: +1-847-8857234 Fax: +1-847-5678907

Received: October 10, 2008 Revised: November 25, 2008

Accepted: December 2, 2008

Published online: January 28, 2009

[com/1007-9327/15/506.asp](http://com/1007-9327/15/506.asp) DOI: <http://dx.doi.org/10.3748/wjg.15.506>

### **Abstract**

The role of *nm23H1* genetic instability is not limited to gastrointestinal malignancies. A similar close relationship exists between *nm23H1* genetic instability and other non gastrointestinal systemic malignancies. For instance, in oral malignant melanomas with lymphoid metastasis, the *nm23H1* expression is significantly lower in contrast to tumors with no lymphoid metastasis. Similarly, increased metastasis is seen in non small cell lung cancers following down regulation of *nm23H1* in conjunction with KAI-1 down regulation. There is an inverse relationship between tumor stage and metastasis and *nm23H1* expression in individuals with prostate carcinomas and a similar relationship exists between microsatellite instability of the *nm23H1* gene and ovarian carcinogenesis. For instance, nearly 70.5% of stage I - II ovarian tumors express *nm23H1* in sharp contrast to only 25% of stage III-IV ovarian tumors. As is clearly evident, *nm23H1* has a major role in gastrointestinal and non-gastrointestinal carcinogenesis. The coming few years will hopefully see the development of new strategies by virtue of which we can alter *nm23H1* expression and thus decrease the risk of metastasis in malignant tumors.

© 2009 The WJG Press and Baishideng. All rights reserved.

**Key words:** *nm23H1*; Non small cell lung cancers; Prostate carcinomas; Nasopharyngeal carcinomas

**Peer reviewer:** Chi-Hin Cho, Chair and Professor, Department of Pharmacology, The University of Hong Kong, 21 Sassoon Road, Hong Kong, China

Kapoor S. *nm23H1* expression and its role in the evolution of non-gastrointestinal malignancies. *World J Gastroenterol* 2009; 15(4): 506-507 Available from: URL: <http://www.wjgnet.com>

### **TO THE EDITOR**

The recent article by Yang *et al*<sup>[1]</sup> about the relationship between gastrointestinal malignancies and *nm23H1* genetic instability is highly interesting. Interestingly, the role of *nm23H1* genetic instability is not limited to gastrointestinal malignancies. In fact, a similar close and intricate relationship exists between *nm23H1* genetic instability and other non gastrointestinal systemic malignancies.

For instance, Korabiowska *et al*<sup>[2]</sup> have shown that the *nm23H1* expression is significantly lower in oral malignant melanomas with lymphoid metastasis than in tumors with no lymphoid metastasis. Similarly, increased metastasis is seen in non small cell lung cancers following down regulation of *nm23H1* in conjunction with KAI-1 down regulation<sup>[3]</sup>. Similarly, there is an inverse relationship between tumor stage and metastasis and *nm23H1* expression in individuals with prostate carcinomas<sup>[4]</sup>. A similar relationship exists between microsatellite instability of the *nm23H1* gene and ovarian carcinogenesis. For instance, nearly 70.5% of stage I - II ovarian tumors express *nm23H1* in sharp contrast to only 25% of stage III-IV ovarian tumors<sup>[5]</sup>.

Similarly, *nm23H1* expression may be used to determine response to treatment. For instance, following radiotherapy, the five-year survival rate in patients with nasopharyngeal carcinomas and high expression of *nm23H1* is 53.2% in comparison to only 22.7% in individuals with low expression of *nm23H1*<sup>[6]</sup>. In fact, transfer of *nm23H1* via adeno viruses is rapidly emerging as a potential therapeutic tool to prevent metastasis. For instance, this method has been shown to decrease metastasis in implantation models of ovarian cancer<sup>[7]</sup>.

As is clearly evident, *nm23H1* plays a major role in gastrointestinal and non-gastrointestinal carcinogenesis. The coming few years will hopefully see the development of new strategies by virtue of which we can alter *nm23H1* expression and thus decrease the risk of metastasis in malignant tumors.

### **REFERENCES**

- 1 Yang YQ, Wu L, Chen JX, Sun JZ, Li M, Li DM, Lu HY,

- Su ZH, Lin XQ, Li JC. Relationship between nm23H1 genetic instability and clinical pathological characteristics in Chinese digestive system cancer patients. *World J Gastroenterol* 2008; **14**: 5549-5556; discussion 5555
- 2 **Korabiowska M**, Honig JF, Jawien J, Knapik J, Stachura J, Cordon-Cardo C, Fischer G. Relationship of nm23 expression to proliferation and prognosis in malignant melanomas of the oral cavity. *In Vivo* 2005; **19**: 1093-1096
- 3 **Goncharuk VN**, del-Rosario A, Kren L, Anwar S, Sheehan CE, Carlson JA, Ross JS. Co-downregulation of PTEN, KAI-1, and nm23-H1 tumor/metastasis suppressor proteins in non-small cell lung cancer. *Ann Diagn Pathol* 2004; **8**: 6-16
- 4 **Ding GF**, Li JC, Xu YF. [Study on the correlation between the expression of nm23H1mRNA, TGF-beta1mRNA and tumor metastases, survival rate with prostate cancer] *Fenzi Xibao Shenguu Xuebao* 2006; **39**: 544-552
- 5 **Yang YQ**, Li JC. [Correlation of genetic instability of nm23H1 gene to clinicopathologic features of epithelial ovarian carcinoma] *Ai Zheng* 2006; **25**: 713-717
- 6 **Wang SL**, Huang HC, Jiang YS, Yang Q. [Expressions and correlation with radiotherapy's effect of five kinds of genes in nasopharyngeal carcinoma] *Zhonghua Erbi Yanhou Toujing Waike Zazhi* 2006; **41**: 542-545
- 7 **Li J**, Zhou J, Chen G, Wang H, Wang S, Xing H, Gao Q, Lu Y, He Y, Ma D. Inhibition of ovarian cancer metastasis by adeno-associated virus-mediated gene transfer of nm23H1 in an orthotopic implantation model. *Cancer Gene Ther* 2006; **13**: 266-272

S- Editor Li LF L- Editor Wang XL E- Editor Ma WH